3,350
-3.32%
Close of 9 Nov 2026, in KRW
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Helixmith Co
Its shares trade on KOSDAQ under the ticker 084990.KQ. It has been listed since 29 December 2005. In the fiscal year to 31 December 2025, it reported revenue of ₩2.60bn and a net loss of ₩434.9m. At that date it held total assets of ₩143.20bn and shareholders' equity of ₩141.98bn.
Helixmith Co., Ltd. engages in the development and sale of bio and natural substances. The company is headquartered in Seoul, Seoul. The company went IPO on 2005-12-29. The firm operates its business through two segments. The Natural Products Business segment develops and sells raw materials for functional materials and health functional foods such as Alex, Murphine, and Nimosin. The New Biopharmaceutical Business segment develops diabetic neuropathy treatment, diabetic ischemic foot ulcer, amyotrophic lateral sclerosis treatment, ischemic heart disease, and anticancer treatment.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Biotechnology
- Listed since
- 29 Dec 2005
- Website
- helixmith.com ↗
Leadership
Pay as last reported
- Mr. Jae Seok ParkDirector
- Mr. Jae Yeong ParkNon-Executive Independent Director
- Mr. Gyeong Guk SeoNon-Executive Independent Director
- Mr. Jin Bin YimNon-Executive Independent Director
- Song Seon JangChairman, Chief Executive Officer, since 2024
- Mr. Byeong Seong KimPresident
- Mr. Hyeong Jun KimChief Financial Officer
- Mr. Jae Gyun JungChief Technology Officer, Director, since 2024
- Gwang Yeop JinInternal Auditor
- Mr. Dong Gyu ChoiDirector
- Mr. Hun Sik KimDirector
- Ms. Jeong Seon LeeDirector
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 12
- Environment
- 13
- Social
- 13
- Governance
- 11
- Carbon reduction policy
- No
- Human rights policy
- No
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Helixmith Co Ltd develops natural substances like Alex, Murphine, and Nimosin for health functional foods.
- The company operates two business segments: Natural Products and New Biopharmaceuticals.
- Helixmith's IPO in 2005 established a strong foundation in the Health Care sector.
Weaknesses
- The company focuses on a limited number of products including Alex, Murphine, and Nimosin.
- Helixmith's business segments are concentrated in specific health treatments like diabetic neuropathy and cancer.
- The firm has no mention of international expansion beyond Seoul, South Korea.
Opportunities
- Helixmith can expand its New Biopharmaceutical Business into diabetic ischemic foot ulcer treatments.
- The Natural Products Business can grow by developing new functional food raw materials.
- Helixmith's presence in the Health Care sector offers opportunities for partnerships in Biotechnology.
Threats
- The company faces competition in the Health Care sector from other biotechnology firms.
- Helixmith's reliance on specific products like Alex, Murphine, and Nimosin poses a risk if demand declines.
- The firm's limited international presence could hinder growth in global markets.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.